WISDOM: Risk-Based Breast Cancer Screening

The WISDOM trial compared risk-based breast cancer screening with annual screening to assess whether screening intensity can be tailored to individual risk. In this MEDtalk, Martin Eklund, PhD, Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden, presents results showing that risk-based screening was non-inferior for the detection of stage 2B or higher breast cancers.